Find Clinical Trials

Inclusion criteria * Adult (age 18 and above) * Student in the University of Helsinki, Finland * Able to speak/read Finnish, Swedish, or English Exclusion criteria: \- None

Inclusion Criteria: * More than 18 years * admission to intensive care for less than 3 days for a neurological lesion * Sensor placement for intracranial pressure monitoring Exclusion Criteria: * patient under judicial protection * refusal to participate * patients under 18 years of age

Inclusion Criteria: * Persons with confirmed multiple sclerosis diagnosis with Expanded Disability Status Scale scores of 4-6.5, characteristic of 2nd stage of multiple sclerosis; * Hypertension defined as elevated, or Stage 1 or 2, as per the 2017 American Heart Association guidelines (brachial systolic blood pressure \> 120 mmHg or brachial diastolic blood pressure \> 80 mmHg) * Persons who are physically inactive (less than 60 min/wk of physical activity); * Persons with body mass index \< 40 kg/m2; * Persons who are not confined to a wheel chair; * Multiple sclerosis relapse in the past 30 days; * People with stable pharmacotherapy. Exclusion Criteria: * People with additional cardiovascular comorbidities; * People with type 1 diabetes mellitus; * Physician disapproval to participating in the study; * Space constraints to fit a cycle ergometer at the home of prospective participants.

Inclusion Criteria: * Adults 18 years and over * Accidental burn injury and meet the criteria for admission to burn centres * Clinician judgment for participation readiness * Ability to provide informed consent Exclusion Criteria: No intentional burn injuries • Lacking capacity to provide informed consent

Inclusion Criteria: * Women with 50 to 65 old years; * Postmenopausal diagnosis (amenorrhea for 12 months or more); * Previous diagnosis of hypertension and treat with medications; * Physically inactive. Exclusion Criteria: * History of other cardiovascular problems (heart failure, heart attack, stroke, etc); * Grade II obesity (BMI ≥ 35 kg/m²); * Medications (beta-blockers and/or non-dihydropyridine calcium channel blockers); * Systolic blood pressure at rest above 160 mmHg and/or dyastolic blood presure above 105 mmHg; * Unable to perform resistance exercise due to musculoskeletal or cognitive reasons.

Inclusion Criteria: 1. Age over 70 years 2. Histologically confirmed diagnosis of BC, any time before study enrollment. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3. 4. Patient considered inoperable in multidisciplinary board decision or refusing surgery. Main criteria determining inoperability are inability to receive general anesthesia after anesthetics and/or surgical evaluation. Criteria described in the statement of American Society of Anesthesiologists (ASA) {, #4699} and American College of Surgeons Surgical risk calculators {, #4695} are usually addressed in the multidisciplinary discussion (Appendix ). 5. Presence of measurable disease in the breast, defined as a lesion that can be accurately measured in at least one dimension with imaging (ultrasound, CT or MRI). Disease in the axilla or internal mammary chain is allowed and will be treated at the discretion of the radiation oncologist. Regional disease is not considered in measurements of local response. 6. Primary tumor accessible to SBRT, as defined by treating radiation oncologist. 7. Neo-adjuvant systemic therapy is allowed. 8. Tumor size in planning computed tomography (CT) permitting SBRT delivery. SBRT appropriateness is defined by the treating radiation oncologist. 9. Multifocality (over two tumor foci within the same breast quadrant) is allowed, as long as the total treatment volumes remain suitable for SBRT, as defined by the treating radiation oncologist. 10. Total tumor treatment volume/ whole breast volume ratio not exceeding 30%. 11. Previous treatment for BC to the contralateral breast is allowed. Previous treatment to the same breast for other reason than BC is allowed. 12. Capacity of patient to collaborate for SBRT delivery. 13. Capacity of patient to understand and sign a written informed consent according to International Council for Harmonization (ICH)/Good Clinical Practice (GCP) regulations before registration. Exclusion Criteria: 1. Prior surgery for the current diagnosis. 2. Prior whole or partial breast irradiation to the involved breast. 3. Absolute contraindication to RT, such as Li-Fraumeni syndrome. 4. Current participation and receipt of study therapy or previous participation in a study of an investigational agent and receipt of study therapy or used an investigation device within 4 weeks of the first day of treatment. 5. Not able to communicate meaningfully with investigator and site staff and/or incapable of discernment. 6. Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. \-

* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids * No planned use of fish oil supplementations * No endocrine-, heart-, kidney- or auto-immune disorders * No disorders requiring treatment with blood thinning medication

Inclusion Criteria: * Consecutive women and men aged 18 years or older with a diagnosis of stage I-III breast cancer (any histological and receptor subtype) * For Clinically Node negative (cN0) at presentation: any axillary staging technique including palpation is allowed. Dual tracer mapping is not required for Sentinel Lymph Node Biopsy (SLNB) * For Clinically Node positive (cN+) at presentation: Biopsy proven confirmation is required. Staging techniques include: SLNB with dual mapping or targeted axillary dissection (Targeted Axillary Dissection, TAD: imaging-guided localization of sampled node in combination with Sentinel Lymph Node procedure with or without dual mapping) or the Marking Axillary Lymph Nodes with Iodine Seeds (MARI) procedure * Completed neoadjuvant chemotherapy * Residual micrometastases detected on SLNB or TAD or MARI (on frozen section or final pathology) * Concomitant presence of Isolated Tumor Cells (ITCs) and micrometastases in other sentinel lymph nodes is allowed * Received axillary treatment with completion axillary lymph node dissection (ALND), axillary Radiotherapy (ART), both or none * At least 1-year follow-up (inclusion should end in May 2023) * Had surgery at any time point until May 2023 at the latest * Prior history of stage I-III (not stage IV) breast cancer is allowed Exclusion Criteria: * Did not undergo SLNB/TAD/MARI (e.g., went straight to ALND or ART) * Presence of ITCs alone or macrometastases on the sentinel nodes (or TAD nodes or MARI node) * Stage IV disease at presentation * Inflammatory breast cancer at presentation * Neoadjuvant endocrine therapy * Micrometastases detected by One-step nucleic acid amplification (OSNA)

Inclusion Criteria: Participants must meet all the following inclusion criteria to participate in this study: * Adults (at least 18 years of age) including both intubated/ventilated and non-intubated patients * Likely to have pathology related to either, abnormal diaphragmatic excursion and lung aeration, pulmonary perfusion, increased lung water content or all the above, as well as for cricopharyngeal dysfunction/swallowing difficulties at risk for aspiration. * The subject or a legally authorized representative has provided written informed consent. Exclusion Criteria: Candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. These criteria are: * Special populations, including women with known pregnancy, prisoners, or institutionalized individuals * Patients where additional radiation is clinically contraindicated * Care team does not provide assent for approaching patient/surrogate * For women of child-bearing potential, defined as premenopausal women, a pregnancy test will be administered to determine pregnancy status and confirm eligibility for the study. A pregnancy test will NOT be administered to women who are post-menopausal or have documentation of surgical sterilization.

Inclusion Criteria: 1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure 2. LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m² 3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or \<50% of predicted peak VO2 value) 4. NYHA Class IIIB or NYHA Class IV 5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months 6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant 7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group Randomization Criteria: 1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days. 2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days. 3. mean PAP ≥ 30 mmHg. 4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant. Single Arm Registry Criteria: 1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial. 2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days. 3. mean PAP \<30 mmHg Exclusion Criteria: 1. Subject is \< 18 years of age at the time of informed consent. 2. Dependent on IV inotrope in the last 30 days. 3. Contra-indications to HM3 LVAS or CardioMEMS HF system. 4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy. 5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter. 6. Existence of ongoing MCS. 7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant. 8. History of any solid organ transplant. 9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management. 10. Presence of an active, uncontrolled infection. 11. Complex congenital heart disease. 12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD. 13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (\>1 episode) pulmonary embolism and/or deep vein thrombosis. 14. Planned VAD or Bi-VAD support prior to enrollment. 15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure: 1. An INR ≥ 2.0 not due to anticoagulation therapy 2. An eGFR \< 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis. 3. Biopsy proven liver cirrhosis. 4. Need for chronic renal replacement therapy. 5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 \< 30% predicted. 6. History of cerebrovascular disease with significant (\> 80%) uncorrected internal carotid stenosis. 7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration. 16. Any condition other than HF that could limit survival to less than 24 months. 17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.

Inclusion Criteria: * Office systolic blood pressure between 130-150 mmHg and/or diastolic blood pressure between 80-95 mmHg * Age between 18 and 75 years * Not currently receiving antihypertensive medication or having discontinued antihypertensive medication for more than two weeks * Able to undergo and complete the transcutaneous electrical acupoint stimulation treatment * Agree to participate and sign the informed consent form Exclusion Criteria: * Pregnant or breastfeeding women * Severe heart conditions, including coronary heart disease, myocardial infarction, arrhythmia, heart failure, or having an implanted cardiac pacemaker * Skin conditions, including eczema, allergic dermatitis, or seborrheic dermatitis * Neuromuscular diseases, mental disorders, epilepsy, or cognitive impairment * Lower limb deep vein thrombosis or thrombophlebitis * Wounds, surgical scars, or malignant tumors at the stimulation areas * Inability to tolerate the transcutaneous electrical acupoint stimulation treatment or allergic to electrical stimulation * Currently participating in other clinical trials

Inclusion Criteria: 1. Patients in whom ECT is clinically indicated: The referrals to ECT by the primary psychiatrist (before a consult by the ECT consultant) will serve to both increase the feasibility of the study and address any ethical concerns that the patient would not undergo ECT without having a valid full indication for the procedure as well as increase the external validity and generalizability of the study. 2. Male or female patients 18 to 90 years of age 3. Current DSM-5 criteria for MDE with any SI of major depressive, bipolar, or schizoaffective disorders 4. Montgomery-Asberg depression rating scale (MADRS) with 2 or more on SI item 5. Use of effective method of birth control for women of child-bearing capacity 6. Patient is medically stable 7. No anticipated need to alter psychotropic medications for the duration of the study (except for urgent/emergent situations) 8. Ability of patient to fully participate in the informed consent process Exclusion Criteria: 1. Unstable or serious medical condition that substantially increases risks of ECT or cognitive impairment 2. Female patients who are pregnant or plan to be pregnant during the study or are breast-feeding 3. History of neurological disorder if deemed by the treating ECT physician or PI to pose a significant risk with ECT, or if there is any metal in the head or history of known structural brain lesion or skull defect that is deemed to affect cognition or safe ECT treatment 4. Implanted devices that make ECT unsafe 5. Clinical presentation of delirium or dementia 6. Active substance use disorders within 1 week of randomization 7. ECT in the past 1 month or prior failure to respond to an adequate course of ECT as deemed by the ECT physician treating the patient or the PI

Inclusion Criteria: 1. Voluntary and competent to consent. 2. Ages 16-19 years old. 3. Can speak and read English. 4. Primary and/or predominant diagnosis of major depressive episode without psychotic features in the current episode, confirmed by The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). 5. Depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant in the current depressive episode. 6. Moderate symptoms in the current depressive episode, indexed by a score of at least 40 on the Children's Depression Rating Scale Revised for depression (CDRS-R). 7. Are able to adhere to the treatment schedule. 8. Have stable psychotropic medications and/or psychotherapy regimen for at least four weeks before participating in the trial. Exclusion Criteria: 1. Diagnosis of bipolar I or II disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria. 2. Current or past substance (\< 3 months) (excluding caffeine or nicotine) or alcohol abuse/dependence, as defined in the DSM-5 criteria. Based on DSM-5 criteria, mild cannabis or alcohol use would be allowed in the past 3 months, moderate to severe would be an exclusion. 3. Current use of illegal substances or cannabis confirmed by urine screening test. 4. Concomitant unstable major medical or neurological disease (e.g., uncontrolled diabetes or renal dysfunction). 5. Organic cause of depressive symptoms (e.g. thyroid dysfunction), ruled out by the treating physician. 6. Acute suicidality or life-threatening due to self-neglect. 7. Are pregnant or breastfeeding, or plan to become pregnant during treatment (pregnancy will be assessed by a urine test). 8. Have a specific contraindication to TMS and/or MRI (e.g., personal history of epilepsy or seizures, metal head implant, pacemaker). 9. Unwilling to maintain the current antidepressant regimen. 10. Taking more than 1 mg/day of lorazepam or equivalent. 11. Any other condition that, in the opinion of the investigators, would impair the participant's ability to complete the study.

Inclusion Criteria: * Subjects who voluntarily participate in this clinical trial and signed the informed consent form (ICF); * Chinese subjects aged 18-75 years (both inclusive) at the time of consent, male or female; * Type 2 diabetes mellitus (clinically diagnosed for more than 6 months); * HbA1c7.0-10.0 % (both inclusive) by central laboratory analysis at the time of screening; * Current treatment for at least 90 calendar days prior to screening with metformin monotherapy or metformin in any combination with 1 additional OADs (including fixed combination): SU, glinides, AGI, SGLT2i or TZD. For ≥ 60 calendar days prior to screening subjects should be on a stable dose of: 1. Metformin (≥ 1500 mg or at maximum tolerated dose) or 2. Metformin (≥1500 mg or max tolerated dose) and SU (≥half of the max approved dose according to local label) or 3. Metformin (≥1500 mg or max tolerated dose) and glinides (≥half of the max approved dose according to local label) or 4. Metformin (≥1500 mg or max tolerated dose) and AGI (≥half of the max approved dose according to local label) or 5. Metformin (≥1500 mg or max tolerated dose) and SGLT2i (≥half of the max approved dose or minimum maintenance dose such as empagliflozin 10 mg and canagliflozin 100 mg according to local label) or 6. Metformin (≥1500 mg or max tolerated dose) and TZD (≥half of the max approved dose according to local label); * Body mass index (BMI) ≥ 19.0 kg/m2 and ≤ 40 kg/m2; * Able and willing to adhere to the protocol including performing self-monitoring of plasma glucose profiles, keeping a trial diary and using a pre-filled pen device. Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from the study: * Subjects with diabetes of other types than T2DM; * Known or suspected hypersensitivity to trial product(s) or related components; * Participated in any clinical trial and Receipt of any treatment of investigational medicinal product (IMP) or medical device within 90 days prior screening; * Treatment with glucose lowering agent(s) other than stated in the inclusion criteria 5 for cumulatively more than 14 days in a period of 90 days before screening; or treatment with these agent(s) in a period of 30 days before screening and might influence the assessment of efficacy of glycemic control (Judged by the investigator); * Treatment with systemic corticosteroid for cumulatively more than 14 days in a period of 90 days before screening (including intravenous, muscle and subcutaneous injections, and oral administration, except for local, intraocular, nasal, intraarticular, and inhalation medications); or treatment with these agent(s) in a period of 30 days before screening and might influence the assessment of efficacy (Judged by the investigator); * Treatment with glucose lowering agent(s) of herbal traditional Chinese medicine or other local herbal medicines for cumulatively more than 14 days in a period of 90 days before screening; or treatment with these agent(s) in a period of 30 days before screening and might influence the assessment of efficacy (Judged by the investigator); * Treated with stable insulin regimen (except for short-term treatment (e.g., no more than 14 days of continuous treatment)), or treatment with insulin in a period of 30 days before screening and might influence the assessment of efficacy (Judged by the investigator); * Treatment with GLP-1 receptor agonists or DPP-4 inhibitors within 90 calendar days prior to screening; * Impaired liver function, defined as aspart aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5 times upper limit of the normal or a total bilirubin level (TBIL) ≥ 1.5 times upper limit of the normal; * Triglycerides \>5.6 mmol/L at screening; * Impaired renal function, defined as creatinine clearance (Ccr) of less than 60 mL/min (calculated from the Cockcroft-Gault formula); * Have had 1 or more episodes of severe hypoglycemia within the 6 months prior to screening. * Have had 1 or more episodes of acute diabetic complications (diabetic ketoacidosis, hyperglycemic hyperosmolar state, diabetic lactic acidosis, etc.) within the 6 months prior to screening. * With concomitant conditions at screening that may affect the evaluation of the study, including cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, liver diseases, kidney diseases, nervous system diseases, psychiatric diseases, hematological diseases, immune system diseases, endocrine system diseases, pancreatic diseases, and/or malignant tumors.

Inclusion Criteria: 1. aged 60 years or older and dwelling in the community; 2. able to communicate in Cantonese; 3. have access to the internet and videoconferencing devices such as a mobile phone; 4. able to give informed consent to participate. Exclusion Criteria: 1. severe emotional distress based on PHQ-4 screening assessment or presenting an imminent suicidal risk; 2. known history of autism, intellectual disability, schizophrenia-spectrum disorder, bipolar disorder, Parkinson's disease, or dementia/significant cognitive impairment; 3. illiterate; 4. difficulty in communication.

Inclusion Criteria: * Clinical diagnosis of Bipolar disorder types I and II diagnosis * Adults of both genders, from 18 to 60 years old * In typical pharmacotherapy for BD, for at least one month * Agreement to participate in the study with signature of the consent form Exclusion Criteria: * Patients with "very good or excellent" diet quality assessed by the diet quality scale (ESQUADA): \>275 out of a score of 375 * Patients in a state of hypomania or mania: score \>8 (Young Mania Rating Scale - YMRS) * Patients with severe depression \>21 Montgomery-Åsberg Depression Rating Scale * Patients at low cardiovascular risk (\<7 points for men or \<9 points for women on the Framingham Global Risk Score) * Low weight or eutrophic body mass index: \<25kg/m² as in similar studies * Pregnant or breastfeeding women * Patients diagnosed with anorexia and bulimia nervosa * Patientes diagnosed with Irritable Bowl Syndrome or other diagnosed conditions that affect the gastrointestinal function

Inclusion Criteria: * All employees working at the company/team/department participating in the study and starting to use the Frendie PRO mobile application within the study period. * Ability to fill the questionnaires online in Finnish Exclusion Criteria: * incapable of using questionnaire online * does not know Finnish well enough to answer the questions

Inclusion Criteria: * Penn Medicine primary care outpatients * Clinical diagnosis of major depressive disorder * A score of 10+ on the Patient Health Questionnaire 9 (PHQ-9) * Age 21 to 64 years at the time of study entry * Prescribed an antidepressant by their primary care clinician * Express interest in taking antidepressant medication * Own a cell phone * Capable of using the electronic pill bottle * English-speaking Exclusion Criteria: * Treated with antidepressants in the past 90 days * Pregnant or breastfeeding * An active substance use disorder other than nicotine * A lifetime history of treatment for bipolar disorder or schizophrenia * Hospital admission or emergency department visit for suicidal symptoms in the past year * Lack capacity to provide informed consent * Using antidepressant more than 10 days at baseline assessment

Inclusion Criteria: * 19 years to 89 years old * Diagnosed diabetes mellitus * Signs or symptoms of neuropathy and maximum baseline visual-analog pain scale ≥ 5 cm and peripheral arterial disease (diagnosed by ankle-brachial index \< 0.90 or vascular imaging studies) with claudication and exertion-induced visual-analog pain scale ≥ 6 cm for a minimum of 3 months * Successful spinal cord stimulator (SCS) trial (\>50% relief of chronic lower extremity pain) and will have a new permanent SCS placed prior to study intervention Exclusion Criteria: * Uncontrolled psychological or psychiatric disorder * Inability to hold antithrombotic therapy per the American Society of Regional Anesthesia guidelines * Non-healing wounds * Gangrene * Critical limb ischemia * Prior lower extremity amputation * Inability to adhere to study follow-up * Mechanical spine instability based on flexion/extension radiographs of the lumbar spine * Prior or current spinal cord stimulator implant

Inclusion Criteria: * Men and women of all races * Age 18 to 65 years * Body mass index (BMI) between 30-45 kg/m2 * Pre-hypertension (defined as two or more seated blood pressure readings \>120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings \>130/80 mmHg or use of antihypertensive medications) * Capable of giving informed consent * Fluent in written and spoken English * Satisfactory history and physical exam Exclusion Criteria: * Age ≤ 17 or ≥ 66 years * Taking more than two antihypertensive medications * Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease) * Pregnant or nursing women * Women taking hormone replacement therapy within 6 months * Decisional impairment * Prisoners * Alcohol or drug abuse * Current smokers * Highly trained athletes * Subjects with \>5% weight change in the past 3 months * BMI \> 45 kg/m2 * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications) * History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack) * History or presence of immunological or hematological disorders * Impaired hepatic function \[aspartate aminotransferase (AST) or alanine transaminase (ALT) levels \>2 times upper limit of normal range\] * Impaired renal function (serum creatinine \>2.0 mg/dl) * Anemia * Treatment with drugs increasing sympathetic activity \[e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants\] * Treatment with phosphodiesterase-5 inhibitors * Treatment with anticoagulants (e.g. warfarin) * Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month) * Treatment with any investigational drug in the 1-month preceding the study * Inability to give, or withdraw, informed consent